CDKN2A and neoplasm: Mice with targeted deletions of p16, p19ARF or both were investigated by several groups suggesting that mouse strains with specific inactivation of p16 or p19ARF were tumor prone but neither genetic loss alone was as severe as those with double knockouts of both of these genes [57,73,74,75].